Home › Compare › RBLAY vs ABBV
RBLAY yields 2.38% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, RBLAY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RBLAY + ABBV for your $10,000?
Robinsons Land Corporation, together with its subsidiaries, acquires, develops, operates, leases, disposes, and sells real estate properties in the Philippines. It operates through Commercial Centers Division, Residential Division, Office Buildings Division, Hotels and Resorts Division, Logistics and Industrial Facilities Division, and Integrated Developments Division. The company is also involved in the development and sale of residential condominium units, as well as horizontal residential projects; and development and leasing of office spaces; ownership and operation of a chain of hotels. In addition, it develops, leases, and manages shopping malls/commercial centers; explores real estate-related infrastructure projects; and develops and leases warehouse and logistics facilities, as well as focuses on strategic land bank acquisition and management. The company was incorporated in 1980 and is based in Quezon City, the Philippines. Robinsons Land Corporation is a subsidiary of JG Summit Holdings, Inc.
Full RBLAY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.